Immunogenicity of the Foldon trimerization domain and efforts to shield it

Protein subunit and mRNA vaccines encoding viral glycoprotein antigens fused to the bacteriophage T4 fibritintrimerization domain are increasingly being tested in human clinical trials. AREXVY and ABRYSVO®, subunit vaccines composed of respiratory syncytial virus (RSV) prefusion F glycoprotein(s) fused to Foldon, are now FDA-approved and regularly administered. However, administration of vaccine antigens containing the Foldon domain has the potential to elicit off-target antibody responses. Here, we demonstrate that protein subunit vaccine antigens RSV F Foldon and influenza hemagglutinin (HA) Foldon elicit antibodies against the Foldon domain. To dampen Foldon-induced antibody responses, we engineered influenza computationally optimized broadly reactive antigen (COBRA) HA proteins with N-glycosylation motif mutations at three different sites in Foldon. Mass spectrometry analyses confirmed partial occupancy of N-glycosylation modifications at two of the three intended sites. Two of the three COBRA HA Foldon mutant antigens demonstrated reduced binding by anti-Foldon monoclonal and polyclonal antibodies compared to the wild-type COBRA HA Foldon. However, mice immunized with the COBRA HA Foldon mutant antigens did not have a significant reduction in the elicitation of anti-Foldon antibodies. Further analysis suggested that some of the observed differences in antibody binding to mutant Foldon antigens can be attributed to differences in protein sequence alone. Altogether, these data suggest that while the N-glycosylation modifications may partially shield the Foldon from reactive antibodies, this shielding does not significantly reduce its immunogenicity in a naïve setting. Importantly, these data highlight that the Foldon trimerization domain is immunogenic, which should be considered during clinical trials of vaccines that contain Foldon.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-11-13
DOI
https://doi.org/10.1371/journal.pone.0362571
Primary Topic
Influenza Virus Research Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Immunogenicity of the Foldon trimerization domain and efforts to shield it

Rebecca M. DuBois, Sara M. O’Rourke, Jarrod J. Mousa, John V. Dzimianski et al.
2 links
PLoS ONE
Influenza Virus Research Studies
article

Immunogenicity of the Foldon trimerization domain and efforts to shield it

Rebecca M. DuBois, Sara M. O’Rourke, Jarrod J. Mousa, John V. Dzimianski, Kevin Delgado-Cunningham, Aaron D. Gingerich, Spencer R. Pierce, Ted M. Ross, Ian Kunkel
article en

Abstract

Protein subunit and mRNA vaccines encoding viral glycoprotein antigens fused to the bacteriophage T4 fibritintrimerization domain are increasingly being tested in human clinical trials. AREXVY and ABRYSVO®, subunit vaccines composed of respiratory syncytial virus (RSV) prefusion F glycoprotein(s) fused to Foldon, are now FDA-approved and regularly administered. However, administration of vaccine antigens containing the Foldon domain has the potential to elicit off-target antibody responses. Here, we demonstrate that protein subunit vaccine antigens RSV F Foldon and influenza hemagglutinin (HA) Foldon elicit antibodies against the Foldon domain. To dampen Foldon-induced antibody responses, we engineered influenza computationally optimized broadly reactive antigen (COBRA) HA proteins with N-glycosylation motif mutations at three different sites in Foldon. Mass spectrometry analyses confirmed partial occupancy of N-glycosylation modifications at two of the three intended sites. Two of the three COBRA HA Foldon mutant antigens demonstrated reduced binding by anti-Foldon monoclonal and polyclonal antibodies compared to the wild-type COBRA HA Foldon. However, mice immunized with the COBRA HA Foldon mutant antigens did not have a significant reduction in the elicitation of anti-Foldon antibodies. Further analysis suggested that some of the observed differences in antibody binding to mutant Foldon antigens can be attributed to differences in protein sequence alone. Altogether, these data suggest that while the N-glycosylation modifications may partially shield the Foldon from reactive antibodies, this shielding does not significantly reduce its immunogenicity in a naïve setting. Importantly, these data highlight that the Foldon trimerization domain is immunogenic, which should be considered during clinical trials of vaccines that contain Foldon.

PLoS ONEVol. 21(11)
Florida State University (US), Cleveland Clinic (US), University of Georgia (US), University of California, Santa Cruz (US), Cleveland Clinic Florida (US), University of Georgia (GE)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases, Cleveland Clinic, National Institutes of Health, University of California, San Francisco, National Institute of Allergy and Infectious Diseases
Good health and well-being
Influenza Virus Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon